Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades

Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming.Novartis (NVS 0.66%) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care, and cardiovascular, renal, and metabolic diseases. With a strong operating history and a diversified business, The pharmaceutical giant could be an attractive stock for more conservative investors. Let's dive in and take a closer look to see why. Novartis has a lot to work with Novartis is one of the world's largest healthcare companies. That alone doesn't make it worth buying, but it speaks to the scale of the business and its historical success. A company doesn't achieve this level of scale and industry dominance by accident. Management is doing something right, and the drugmaker has been operating at a high level for years. Image source: Getty Images. Notably, Novartis is currently offering investors an attractive 2.9% dividend yield. That is far above the 1.1% of the S&P 500 index and the 1.7% average for the pharmaceutical sector. The dividend has been steadily increasing, though not annually, for over 20 years. Meanwhile, the payout ratio is around 45%, which is entirely reasonable. Notably, over the past two decades, the payout ratio has never exceeded 100%. Basically, this is a relatively high-yield pharmaceutical stock that has a pretty conservative dividend profile. ExpandNYSE: NVSNovartisToday's Change(-0.66%) $-1.08Current Price$162.84Key Data PointsMarket Cap$310BDay's Range$161.80 - $163.6452wk Range$97.72 - $167.86Volume75KAvg Vol1.9MGross Margin75.02%Dividend Yield2.46% There are going to be ups and downs So, from a big-picture perspective, Novartis is the kind of dividend stock that will let you sleep well at night. However, investors shouldn't ignore the fact that it operates in a highly technical and competitive industry. The drugs it develops also have limited patent-protection windows, so it has to innovate constantly. And right now, older drugs are losing share to generic competition, leading revenue to flatline. However, the company has also highlighted five drugs that are advancing through the pipeline or are gaining new indications. Basically, Novartis looks well on its way to offsetting the future revenue losses that come with patent expirations. In the end, this is just the way the pharma industry works, and Novartis is used to navigating these ebbs and flows while rewarding dividend investors well for sticking around. A core holding for conservative dividend investors Novartis isn't likely to be an exciting stock. That's purposeful, as management is clearly trying to build a sustainable, industry-leading business. If you invest for income and don't want to worry about sleepless nights, this giant pharma stock could be the perfect addition to your diversified dividend-stock portfolio.Read NextJan 8, 2026 •By David Jagielski, CPANew Investors: 3 Stocks to Build Your Portfolio Around in 2026Dec 22, 2025 •By Prosper Junior Bakiny2 Top Stocks to Buy and Hold for the Long TermNov 25, 2025 •By Eric VolkmanWhy Novartis Stock Topped the Market TodayOct 4, 2025 •By Prosper Junior Bakiny2 Surefire Dividend Stocks to Buy for the Long HaulJan 31, 2025 •By Motley Fool TranscribingNovartis Ag (NVS) Q4 2024 Earnings Call TranscriptOct 29, 2024 •By Motley Fool TranscribingNovartis Ag (NVS) Q3 2024 Earnings Call TranscriptAbout the AuthorReuben Gregg Brewer is a contributing Motley Fool stock market analyst covering energy, utilities, REITs, and consumer staples. He is the former director of research at Value Line Publishing, where he rose from mutual fund analyst to equity analyst before leading all research operations. Reuben holds a bachelor’s degree in psychology from SUNY Purchase, a master’s in social work from Columbia University, and an MBA from Regis University. He has been featured as a financial expert on CNBC and in the Financial Times, Barron’s, and InvestmentNews.TMFReubenGBrewerStocks MentionedNovartisNYSE: NVS$162.84 (0.66%) $1.08*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.